Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
This approach maximizes initial results while minimizing long-term injection burden
6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs
It works best when combined with adequate hydration, nutrition, and reducing ongoing toxin exposure
May Improve Cardiovascular Health Some studies suggest semaglutide can lower the risk of heart-related issues by improving cholesterol levels and reducing inflammation
US$ 24.23
US$ 21.32
US$ 23.77
US$ 24.15
US$ 24.82
